Cryolife Inc (CRY) reported quarterly earnings results on Wednesday, Apr-27-2016. The company said it had a profit of $0.10 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $0.04. The company posted revenue of $43.00 million in the period, compared to analysts expectations of $41.32 million. The company’s revenue was up 27.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.01 EPS.
Many Wall Street Analysts have commented on Cryolife Inc. Cryolife Inc was Resumed by Piper Jaffray to “Overweight” on Apr 21, 2016. Canaccord Genuity Initiated Cryolife Inc on Apr 13, 2016 to “Buy”, Price Target of the shares are set at $14.
Cryolife Inc closed down -0.06 points or -0.48% at $12.44 with 1,31,526 shares getting traded on Friday. Post opening the session at $12.66, the shares hit an intraday low of $12.27 and an intraday high of $12.66 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Apr 19, 2016, C Elkins Ronald (director) sold 1,000 shares at $12.00 per share price. According to the SEC, on Mar 4, 2016, James P Mackin (CEO) purchased 10,000 shares at $10.91 per share price. On Mar 1, 2016, David C Gale (VP, Research & Development) sold 150 shares at $9.97 per share price, according to the Form-4 filing with the securities and exchange commission.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.